Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Brown, Nicholas ^a   McBain, Catherine ^b   Nash, Stephen ^c   Hopkins, Kirsten ^d   Sanghera, Paul ^e   Saran, Frank ^f   Phillips, Mark ^c   Dungey, Fiona ^c   Clifton Hadley, Laura ^c   Wanek, Katharina ^c   Krell, Daniel ^g   Jeffries, Sarah ^h   Khan, Iftekhar ^c   Smith, Paul ^c   Mulholland, Paul ⁱ  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CEDIRANIB; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GEFITINIB; PLACEBO; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

ADULT; AGED; ANOREXIA; ARTICLE; ATAXIA; BLEEDING; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONFUSION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHASIA; EYE DISEASE; FALLING; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INFECTION; INVOLUNTARY MOVEMENT; LYMPHOCYTOPENIA; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; ORAL MUCOSITIS; OVERALL SURVIVAL; PAIN; PARALLEL DESIGN; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PUSTULE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS; SIDE EFFECT; SKIN ULCER; STOMATITIS; SURVIVAL TIME; THROMBOEMBOLISM; TUMOR RECURRENCE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RECURRENT DISEASE; SAFETY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PLACEBOS; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; SAFETY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84971592109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156369     Document Type: Article

References (50)

1. Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP, et al. Glioblastoma in England: 2007-2011. Eur J Cancer. 2015; 51(4):533-42. doi: 10.1016/j.ejca.2014.12.014 PMID: 25661102.
2. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neurooncology. 2015; 17 Suppl 4:iv1-iv62. doi: 10.1093/neuonc/nov189 PMID: 26511214.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10):987-96. doi: 10.1056/NEJMoa043330 PMID: 15758009.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009; 10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895.
5. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. PMID: 11597399.
6. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985; 313(5998):144-7. PMID: 2981413.
7. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proceedings of the National Academy of Sciences of the United States of America. 1987; 84 (19):6899-903. PMID: 3477813; PubMed Central PMCID: PMC299192.
8. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer research. 1991; 51(8):2164-72. PMID: 2009534.
9. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer research. 2000; 60(5):1383-7. PMID: 10728703.
10. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(16):2288-94. doi: 10.1200/JCO.2006.08.0705 PMID: 17538175.
11. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89(7):2965-9. PMID: 1557402; PubMed Central PMCID: PMC48784.
12. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. Journal of neuro-oncology. 2003; 62(3):297-303. PMID: 12777082.
13. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. Journal of neuropathology and experimental neurology. 2006; 65(6):529-39. PMID: 16783163.
14. Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, et al. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer research. 2006; 66(14):7067-74. doi: 10.1158/0008-5472.CAN-06-0346 PMID: 16849552; PubMed Central PMCID: PMC2610484.
15. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nature reviews Neuroscience. 2007; 8(8):610-22. doi: 10.1038/nrn2175 PMID: 17643088.
16. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(30):4722-9. doi: 10.1200/JCO.2007.12.2440 PMID: 17947719.
17. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(28):4733-40. doi: 10.1200/JCO.2008.19.8721 PMID: 19720927.
18. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(22):5612-9. doi: 10.1158/1078-0432.CCR-14-0834 PMID: 25398844; PubMed Central PMCID: PMC4234180.
19. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer research. 2005; 65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409 PMID: 15899831.
20. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(26):3212-8. doi: 10.1200/JCO.2012.47.2464 PMID: 23940216; PubMed Central PMCID: PMC4021043.
21. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22(1):133-42. doi: 10.1200/JCO.2004.08.110 PMID: 14638850.
22. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British journal of cancer. 2007; 96(7):1047-51. doi: 10.1038/sj.bjc.6603669 PMID: 17353924; PubMed Central PMCID: PMC2360116.
23. van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer. 2010; 46(5):901-11. doi: 10.1016/j.ejca.2009.12.023 PMID: 20061136.
24. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(11):1963-72. doi: 10.1200/JCO.2009.26.3541 PMID: 20231676.
25. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncology. 2004; 6(3):227-35. Epub 07/29. doi: 10.1215/s1152851703000620 PMID: 15279715.
26. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(18):2601-6. Epub 06/20. doi: 10.1200/jco.2006.08.1661 PMID: 17577040.
27. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. The Lancet Oncology. 2007; 9(1):29-38. Epub 12/18. doi: 10.1016/s1470-2045(07)70384-4 PMID: 18082451.
28. Brandes AA, Bartolotti M, Franceschi E. Second surgery for recurrent glioblastoma: advantages and pitfalls. Expert review of anticancer therapy. 2013; 13(5):583-7. Epub 04/27.
29. Mulholland PJ, Thirlwell C, Brock CS, Newlands ES. Emerging targeted treatments for malignant glioma. Expert opinion on emerging drugs. 2005; 10(4):845-54. doi: 10.1517/14728214.10.4.845 PMID: 16262566.
30. Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung cancer. 2003; 41(2):227-31. PMID: 12871787.
31. Forshew T, Lewis P, Waldman A, Peterson D, Glaser M, Brock C, et al. Three different brain tumours evolving from a common origin. Oncogenesis. 2013; 2:e41. doi: 10.1038/oncsis.2013.1 PMID: 23545860; PubMed Central PMCID: PMC3641358.
32. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia. 2009; 11 (5):448-58, 2 p following 58. PMID: 19412429; PubMed Central PMCID: PMC2671857.
33. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Molecular cancer research: MCR. 2007; 5(3):203-20. doi: 10.1158/1541-7786.MCR-06-0404 PMID: 17374728.
34. Scagliotti GV. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2007; 18 Suppl 10:x32-41. doi: 10.1093/annonc/mdm412 PMID: 17761722.
35. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. International journal of cancer Journal international du cancer. 2005; 117(6):883-8. doi: 10.1002/ijc.21479 PMID: 16152621.
36. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematology/oncology clinics of North America. 2004; 18(5):1007-21, viii. doi: 10.1016/j.hoc.2004.06.002 PMID: 15474332.
37. Akagi M, Kawaguchi M, Liu W, McCarty MF, Takeda A, Fan F, et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. British journal of cancer. 2003; 88(5):796-802. doi: 10.1038/sj.bjc.6600811 PMID: 12618892; PubMed Central PMCID: PMC2376351.
38. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5(2):257-65. PMID: 10037173.
39. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, et al. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer. 2003; 98(4):720-9. doi: 10.1002/cncr.11560 PMID: 12910515.
40. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer research. 2000; 60(20):5879-86. PMID: 11059786.
41. Clarke K, Smith K, Gullick WJ, Harris AL. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. British journal of cancer. 2001; 84(10):1322-9. doi: 10.1054/bjoc.2001.1805 PMID: 11355942; PubMed Central PMCID: PMC2363647.
42. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer research. 2003; 63(1):236-41. PMID: 12517803.
43. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical cancer research: an official journal of the American Association for Cancer Research. 2001; 7(5):1459-65. PMID: 11350918.
44. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. British journal of cancer. 2008; 98(5):923-30. doi: 10.1038/sj.bjc.6604269 PMID: 18319715; PubMed Central PMCID: PMC2266842.
45. Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Laboratory investigation; a journal of technical methods and pathology. 2006; 86 (10):981-6. doi: 10.1038/labinvest.3700466 PMID: 16924245.
46. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(1):397-405. PMID: 15671571.
47. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer research. 2001; 61(13):5090-101. PMID: 11431346.
48. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10(2):784-93. PMID: 14760102.
49. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904 PMID: 19447865; PubMed Central PMCID: PMC2893040.
50. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2006; 17 Suppl 7:vii109-14. doi: 10.1093/annonc/mdl962 PMID: 16760272.